文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

将高血压多组分干预整合到新加坡基层医疗服务中——一项整群随机对照试验

Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore-A cluster randomized controlled trial.
PubMed 文献 · PLoS Med · 2022-06-13

在新加坡8家政府诊所开展整群随机对照试验,纳入916例≥40岁血压未控制的高血压患者。干预组接受医生风险分层治疗培训、补贴的氯沙坦-氢氯噻嗪单片复方制剂、护士动机性对话培训及电话随访。24个月时干预组平均收缩压较常规护理组显著降低3.3 mmHg,血压控制率更高。

要点

  • 干预组24个月时平均收缩压较常规护理组显著降低3.3 mmHg(95%CI:-6.34,-0.32;p=0.03)。
  • 干预组血压控制率更高(OR 1.51;95%CI:1.10,2.09;p=0.01)。
  • 干预组10年心血管风险评分>20%的比值更低(OR 0.67;95%CI:0.47,0.97;p=0.03)。

核心结论

  • 由接受风险分层治疗培训的医生、补贴的单片复方制剂、护士实施的动机性对话及电话随访组成的多组分干预改善了血压控制并降低了心血管风险。
  • 作者认为,广泛实施类似本试验的多组分干预可能降低全球高血压相关发病率和死亡率。

研究设计与样本

  • 在新加坡8家政府诊所开展的整群随机对照试验,4家诊所(447例)随机分配至干预组,4家(469例)分配至常规护理组。
  • 纳入916例年龄≥40岁、血压未控制(收缩压≥140 mmHg或舒张压≥90 mmHg)的高血压患者。
  • 患者入组于2017年1月开始,随访时间为2018年12月至2020年9月,分析采用意向性治疗原则。
  • 主要结局为基线后24个月时的平均收缩压,采用似然为基础的线性混合模型重复测量分析。
  • 共766例(83.6%)患者完成2年随访;干预组63例(14.1%)、常规护理组87例(18.6%)失访。

主要发现

  • 24个月时,干预组调整后平均收缩压较常规护理组显著降低(-3.3 mmHg;95%CI:-6.34,-0.32;p=0.03)。
  • 干预组血压控制率更高(OR 1.51;95%CI:1.10,2.09;p=0.01)。
  • 干预组10年心血管风险评分>20%的比值更低(OR 0.67;95%CI:0.47,0.97;p=0.03)。
  • 干预组平均对数白蛋白尿更低(-0.22;95%CI:-0.41,-0.02;p=0.03)。
  • 平均舒张压、死亡率及包括住院在内的严重不良事件两组间无差异。

关键数值与推荐

  • 干预组24个月调整后平均收缩压较常规护理组降低3.3 mmHg(95%CI:-6.34,-0.32;p=0.03)。
  • 干预组血压控制OR为1.51(95%CI:1.10,2.09;p=0.01)。
  • 干预组10年心血管风险评分>20%的OR为0.67(95%CI:0.47,0.97;p=0.03)。
  • 干预组平均对数白蛋白尿变化为-0.22(95%CI:-0.41,-0.02;p=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验的主要局限性为未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite availability of clinical practice guidelines for hypertension management, blood pressure (BP) control remains sub-optimal (<30%) even in high-income countries. This study aims to assess the effectiveness of a potentially scalable multicomponent intervention integrated into primary care system compared to usual care on BP control. METHODS AND FINDINGS: A cluster-randomized controlled trial was conducted in 8 government clinics in Singapore. The trial enrolled 916 patients aged ≥40 years with uncontrolled hypertension (systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg). Multicomponent intervention consisted of physician training in risk-based treatment of hypertension, subsidized losartan-HCTZ single-pill combination (SPC) medications, nurse training in motivational conversations (MCs), and telephone follow-ups. Usual care (controls) comprised of routine care in the clinics, no MC or telephone follow-ups, and no subsidy on SPCs. The primary outcome was mean SBP at 24 months' post-baseline. Four clinics (447 patients) were randomized to intervention and 4 (469) to usual care. Patient enrolment commenced in January 2017, and follow-up was during December 2018 to September 2020. Analysis used intention-to-treat principles. The primary outcome was SBP at 24 months. BP at baseline, 12 and 24 months was modeled at the patient level in a likelihood-based, linear mixed model repeated measures analysis with treatment group, follow-up, treatment group × follow-up interaction as fixed effects, and random cluster (clinic) effects. A total of 766 (83.6%) patients completed 2-year follow-up. A total of 63 (14.1%) and 87 (18.6%) patients in intervention and in usual care, respectively, were lost to follow-up. At 24 months, the adjusted mean SBP was significantly lower in the intervention group compared to usual care (-3.3 mmHg; 95% CI: -6.34, -0.32; p = 0.03). The intervention led to higher BP control (odds ratio 1.51; 95% CI: 1.10, 2.09; p = 0.01), lower odds of high (>20%) 10-year cardiovascular risk score (OR 0.67; 95% CI: 0.47, 0.97; p = 0.03), and lower mean log albuminuria (-0.22; 95% CI: -0.41, -0.02; p = 0.03). Mean DBP, mortality rates, and serious adverse events including hospitalizations were not different between groups. The main limitation was no masking in the trial. CONCLUSIONS: A multicomponent intervention consisting of physicians trained in risk-based treatment, subsidized SPC medications, nurse-delivered motivational conversation, and telephone follow-ups improved BP control and lowered cardiovascular risk. Wide-scale implementation of a multicomponent intervention such as the one in our trial is likely to reduce hypertension-related morbidity and mortality globally. TRIAL REGISTRATION: Trial Registration: Clinicaltrials.gov NCT02972619.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jafar TH, Tan NC, Shirore RM, et al. Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore-A cluster randomized controlled trial. PLoS Med. 2022. PMID: 35696440. doi:10.1371/journal.pmed.1004026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。